Abstract: The present invention relates to a pharmaceutical composition for preventing or treating pancreatic cancer associated with a RON mutation and a method using the same. The pharmaceutical composition for preventing or treating cancer according to the present invention may be applied to patients with pancreatic cancer in which a RON mutation is present. In particular, the present invention may be usefully used as a precision medicine for patients with pancreatic cancer which has resistance to cetuximab used in conventional anticancer therapy and has the RON?155, RON?160, or RON?165 mutation.

Abstract: An oxo-pyridine fusion ring compound of chemical formula 1 or a pharmaceutically acceptable salt thereof effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines.

Abstract: The present invention discloses a method for forming metal lines in a semiconductor device. A plurality of metal lines are densely formed by using Al or Al alloy as a material and performing a reactive ion etching process using a low-k dielectric layer as hard mask patterns. Barrier metal layers are formed on the sidewalls of the metal lines. A low dielectric interlayer insulation film is formed when the low dielectric hard mask patterns exist. It is thus possible to obtain margins in a line process and gains in a critical value of the interlayer insulation film for insulating the metal lines. Therefore, a RC delay time can be reduced by restricting crosstalk between the metal lines and decreasing a capacitance between the metal lines.